Entrada Therapeutics Inc. Common Stock

Entrada Therapeutics Inc. a biotechnology company develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide antibody and enzyme-based programs. The company's lead therapeutic candidates which include ENTR-601-44 and ENTR-601-45 which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501 an intracellular thymidine phosphorylase enzyme replacement therapy which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701 which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research develop manufacture and commercialize ENTR-701. The company was formerly known as CycloPorters Inc. and changed its name to Entrada Therapeutics Inc. in October 2017. Entrada Therapeutics Inc. was incorporated in 2016 and is headquartered in Boston Massachusetts.